JAK1 and neoplasm: Ruxolitinib, a selective JAK1/2 kinase inhibitor known to suppress JAK-STAT signaling (41), was used to assess the role of tumor-intrinsic IFN signaling in the elevated release of ICAM-1 and CXCL10.